Combining Immunotherapy with Transarterial Radioembolization

Hepatocellular carcinoma (HCC) has a high mortality rate due to the diagnosis of patients at advanced stages and ineffective systemic therapies. Immunotherapy is considered a new treatment option for unresectable HCC alternatives to the limitations of conventional cytotoxic chemotherapy. In this cas...

Descripción completa

Detalles Bibliográficos
Autores principales: Balaban Genc, Zeynep Ceren, Soydemır, Efe, Ersoy, Seval Ay, Ones, Tunc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348490/
https://www.ncbi.nlm.nih.gov/pubmed/37456187
http://dx.doi.org/10.4103/ijnm.ijnm_180_22
_version_ 1785073675579424768
author Balaban Genc, Zeynep Ceren
Soydemır, Efe
Ersoy, Seval Ay
Ones, Tunc
author_facet Balaban Genc, Zeynep Ceren
Soydemır, Efe
Ersoy, Seval Ay
Ones, Tunc
author_sort Balaban Genc, Zeynep Ceren
collection PubMed
description Hepatocellular carcinoma (HCC) has a high mortality rate due to the diagnosis of patients at advanced stages and ineffective systemic therapies. Immunotherapy is considered a new treatment option for unresectable HCC alternatives to the limitations of conventional cytotoxic chemotherapy. In this case report, we reported that transarterial radioembolization and immunotherapy such as atezolizumab and bevacizumab can be used together in a manner effectively in the management of HCC treatment.
format Online
Article
Text
id pubmed-10348490
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-103484902023-07-15 Combining Immunotherapy with Transarterial Radioembolization Balaban Genc, Zeynep Ceren Soydemır, Efe Ersoy, Seval Ay Ones, Tunc Indian J Nucl Med Case Report Hepatocellular carcinoma (HCC) has a high mortality rate due to the diagnosis of patients at advanced stages and ineffective systemic therapies. Immunotherapy is considered a new treatment option for unresectable HCC alternatives to the limitations of conventional cytotoxic chemotherapy. In this case report, we reported that transarterial radioembolization and immunotherapy such as atezolizumab and bevacizumab can be used together in a manner effectively in the management of HCC treatment. Wolters Kluwer - Medknow 2023 2023-06-08 /pmc/articles/PMC10348490/ /pubmed/37456187 http://dx.doi.org/10.4103/ijnm.ijnm_180_22 Text en Copyright: © 2023 Indian Journal of Nuclear Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Balaban Genc, Zeynep Ceren
Soydemır, Efe
Ersoy, Seval Ay
Ones, Tunc
Combining Immunotherapy with Transarterial Radioembolization
title Combining Immunotherapy with Transarterial Radioembolization
title_full Combining Immunotherapy with Transarterial Radioembolization
title_fullStr Combining Immunotherapy with Transarterial Radioembolization
title_full_unstemmed Combining Immunotherapy with Transarterial Radioembolization
title_short Combining Immunotherapy with Transarterial Radioembolization
title_sort combining immunotherapy with transarterial radioembolization
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348490/
https://www.ncbi.nlm.nih.gov/pubmed/37456187
http://dx.doi.org/10.4103/ijnm.ijnm_180_22
work_keys_str_mv AT balabangenczeynepceren combiningimmunotherapywithtransarterialradioembolization
AT soydemırefe combiningimmunotherapywithtransarterialradioembolization
AT ersoysevalay combiningimmunotherapywithtransarterialradioembolization
AT onestunc combiningimmunotherapywithtransarterialradioembolization

Ejemplares similares